Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to -$8.1 million.

  • Collegium Pharmaceutical's Change in Accured Expenses rose 87.11% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 103.91%. This contributed to the annual value of -$39.5 million for FY2024, which is 6394.59% down from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Change in Accured Expenses is -$8.1 million, which was down 245.23% from $5.6 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Change in Accured Expenses high stood at $22.4 million for Q4 2024, and its period low was -$62.9 million during Q3 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was $322,000 (2024), whereas its average is -$5.4 million.
  • Data for Collegium Pharmaceutical's Change in Accured Expenses shows a peak YoY increase of 1,635.09% (in 2025) and a maximum YoY decrease of 2,777.73% (in 2025) over the last 5 years.
  • Over the past 5 years, Collegium Pharmaceutical's Change in Accured Expenses (Quarterly) stood at $10.8 million in 2021, then increased by 25.76% to $13.6 million in 2022, then slumped by 62.42% to $5.1 million in 2023, then spiked by 339.04% to $22.4 million in 2024, then skyrocketed by 87.11% to -$8.1 million in 2025.
  • Its Change in Accured Expenses stands at -$8.1 million for Q3 2025, versus $5.6 million for Q2 2025 and -$17.7 million for Q1 2025.